Disclosures: Luca Fabris: Nothing to Disclose, Camilla Venturin: Nothing to Disclose, Yahima Frin-Herrera: Nothing to Disclose, Massimiliano Cadamuro: Nothing to Disclose, Claudia Mescoli: Nothing to Disclose, Umberto Cillo: Nothing to Disclose, Enrico Gringeri: Nothing to Disclose, Elena Campello: Nothing to Disclose, Mario Strazzabosco: Nothing to Disclose, Diego Calvisi: Nothing to Disclose, Antonio Cigliano: Nothing to Disclose, Paolo Simioni: Nothing to Disclose 1938 TRANSPOSON-BASED ONCOGENES INTEGRATION IN ABCB4 (MDR2)-/- MICE RECAPITULATES HIGH SUSCEPTIBILITY TO CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS Pinzhu Huang 1 Guangyan Wei 1 Jesse Kirkpatrick 2 MARAM ALENZI 1 Yi Lin 1 Li Tan 1 Disha Badlani 1 Li Chen 3 Mathieu Petitijean 3 Kahini Vaid 1 Shuangshuang Zhao 1 Alicia lugovskoy 1 Xin Chen 4 Gregory Gores 4 Yury Popov 1 , 1 Division of Gastroenterology and Hepatology, BIDMC, Harvard Medical School, 2 Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 3 PharmaNest, Inc, NJ, 4 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN Background: Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC), difficult to diagnose and associated with high mortality
Abstract Background Despite the effectiveness of glucagon-like peptide-1 agonist (GLP-1A) in the treatment of diabetes, its large molecular weight and high hydrophilicity result in poor cellular permeability, thus limiting its oral bioavailability
While California, New Hampshire, Pennsylvania, and South Carolina stopped covering adult GLP-1 prescriptions for obesity on Jan
Some of our preliminary observations in 2026 suggest that the steady, continuous delivery of a patch may actually lessen the intensity of these side effects for some patients, as it avoids the sharp peak in medication concentration that occurs a day or two after an injection
This question concerns many patients considering tirzepatide for weight management
As of April 2, Costco members can sign up for the service, which runs $179 for three months
